Jane B. Neckers

Jane B.Neckers
Staff Scientist
Developmental Therapeutics Branch
Facility Head, Translational Pharmacodynamics Research Group

Jane Trepel came to the NCI from the Laboratory of Preclinical Pharmacology, National Institute of Mental Health, where she identified posttranslational modification of glycoprotein hormones by ADP-ribosylation. Since then she has held positions of increasing responsibility in the former Clinical Pharmacology Branch and Medicine Branch. She is the author of five issued and pending patents in new drug development and is the recipient of a Federal Technology Transfer Award. Her interests are focused on the new therapeutic opportunities provided by molecular dissection of aberrant tumor cell signaling pathways.

Areas of Expertise
drug development

Contact Info

Jane B. Neckers
Center for Cancer Research
National Cancer Institute
Building 10 - Magnuson CC, Room 12N230
Bethesda, MD 20892
Ph: 240-760-6330
trepelj@mail.nih.gov
Permalink

Selected Publications

  1. Contributions of co-chaperones and post-translational modifications towards Hsp90 drug sensitivity.
    Walton-Diaz A, Khan S, Bourboulia D, Trepel JB, Neckers L, Mollapour M.
    Future Med Chem. 5: 1059-71, 2013. [ Journal Article ]
  2. Molecular chaperone TRAP1 regulates a metabolic switch between mitochondrial respiration and aerobic glycolysis.
    Yoshida S, Tsutsumi S, Muhlebach G, Sourbier C, Lee MJ, Lee S, Vartholomaiou E, Tatokoro M, Beebe K, Miyajima N, Mohney RP, Chen Y, Hasumi H, Xu W, Fukushima H, Nakamura K, Koga F, Kihara K, Trepel J, Picard D, Neckers L.
    Proc. Natl. Acad. Sci. U.S.A.. 110: E1604-12, 2013. [ Journal Article ]
  3. Posttranslational modification and conformational state of Heat Shock Protein 90 differentially affect binding of chemically diverse small molecule inhibitors.
    Beebe K, Mollapour M, Scroggins B, Prodromou C, Xu W, Tokita M, Taldone T, Pullen L, Zierer BK, Lee MJ, Trepel J, Buchner J, Bolon D, Chiosis G, Neckers L.
    Oncotarget. 4: 1065-74, 2013. [ Journal Article ]
  4. A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma.
    Korde N, Carlsten M, Lee MJ, Minter A, Tan E, Kwok M, Manasanch E, Bhutani M, Tageja N, Roschewski M, Zingone A, Costello R, Mulquin M, Zuchlinski D, Maric I, Calvo KR, Braylan R, Tembhare P, Yuan C, Stetler-Stevenson M, Trepel J, Childs R, Landgren O.
    Haematologica. 99: e81-3, 2014. [ Journal Article ]
  5. Asymmetric Hsp90 N domain SUMOylation recruits Aha1 and ATP-competitive inhibitors.
    Mollapour M, Bourboulia D, Beebe K, Woodford MR, Polier S, Hoang A, Chelluri R, Li Y, Guo A, Lee MJ, Fotooh-Abadi E, Khan S, Prince T, Miyajima N, Yoshida S, Tsutsumi S, Xu W, Panaretou B, Stetler-Stevenson WG, Bratslavsky G, Trepel JB, Prodromou C, Neckers L.
    Mol. Cell. 53: 317-29, 2014. [ Journal Article ]

Jane Trepel came to the NCI from the Laboratory of Preclinical Pharmacology, National Institute of Mental Health, where she identified posttranslational modification of glycoprotein hormones by ADP-ribosylation. Since then she has held positions of increasing responsibility in the former Clinical Pharmacology Branch and Medicine Branch. She is the author of five issued and pending patents in new drug development and is the recipient of a Federal Technology Transfer Award. Her interests are focused on the new therapeutic opportunities provided by molecular dissection of aberrant tumor cell signaling pathways.

Name Position
Jonathan Baker Postbaccalaureate Fellow (CRTA)
Min-Jung Lee Ph.D. Research Collaborator
Sunmin Lee Ph.D. Research Chemist
Akira Yuno Ph.D. Postdoctoral Fellow (Visiting)